Furthermore, pharmacological suppression of NADPH oxidase (NOX), an enzymatic complex capable of oxidizing NAPH or NADH to NADP+ or NAD+, directly impacts cancer cell mitochondria, leading to a decrease in cellular glycolysis and a loss of cell viability and growth (Lu et al., 2012). The gene discussed is FMO5; the disease is cancer.